Form 4: Akari Director Acquires Warrants, Converts Debt

Akari Therapeutics director Sandip Patel acquired warrants and pre-funded warrants, including some through a private placement and others by converting an outstanding promissory note.

Summary

• Director Sandip Patel acquired various warrants and pre-funded warrants on December 16, 2025.
• This includes 247,462 pre-funded warrants (PIPE PFWs) and 247,462 Series G Warrants through a private placement at a combined purchase price of $0.4041 per unit.
• Additionally, Patel received 154,664 pre-funded warrants (Note Exchange Unregistered Pre-Funded Warrants) and 160,958 unregistered warrants (Note Exchange Unregistered Warrants) in exchange for an unsecured promissory note.
• All these warrants and pre-funded warrants become exercisable upon shareholder approval.
• The Series G Warrants and Note Exchange Unregistered Warrants have a five-year term from approval, while the pre-funded warrants are exercisable until fully exercised.
• The exercise price for the Series G Warrants and Note Exchange Unregistered Warrants is $0.3883 per American Depositary Share (ADS), and for the pre-funded warrants, it is $0.00001 per ADS.
• Each American Depositary Share (ADS) represents 2,000 Ordinary Shares.

Sentiment

Score: 6

Explanation: The director's acquisition of warrants, particularly through the conversion of a promissory note, signals confidence and helps manage the company's debt structure. However, the reliance on warrants and the need for shareholder approval introduce elements of uncertainty and potential future dilution.

Positives

• Director Sandip Patel's acquisition of warrants and pre-funded warrants, particularly through the conversion of a promissory note, demonstrates a continued commitment and belief in the company's future.
• The conversion of debt into equity-like instruments (warrants) can reduce the company's immediate debt burden and improve its balance sheet liquidity.
• The private placement indicates a capital infusion, albeit through warrants, which can provide future funding upon exercise.

Negatives

• The need for a private placement and debt-to-warrant conversion might suggest the company is seeking alternative financing methods, potentially due to challenges in securing traditional equity or debt.
• The exercisability of all warrants being contingent on shareholder approval introduces a potential delay or uncertainty in the full realization of these transactions.
• The issuance of warrants could lead to future dilution for existing shareholders if exercised.

Risks

• The exercisability of the warrants and pre-funded warrants is contingent upon future shareholder approval, introducing a risk of delay or non-approval.
• Future dilution for existing shareholders if the warrants are exercised.

Future Outlook

The exercisability of the newly acquired warrants and pre-funded warrants is contingent upon future shareholder approval, which will determine the timing of potential capital infusion and dilution.

Management Comments

• Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0. per Ordinary Share of the Issuer.
• The Series G Warrants and the PIPE PFWs shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised.
• The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised.

Industry Context

This transaction, involving a director's acquisition of warrants and conversion of debt, is common in smaller biotechnology or pharmaceutical companies like Akari Therapeutics, which often rely on private placements and creative financing to fund research and development, especially when traditional funding sources are constrained. It reflects a strategy to manage capital structure and secure future funding while potentially deferring immediate cash outflows.

Comparison to Industry Standards

• NA This filing is an insider transaction report (Form 4) and does not contain operational or financial results that can be directly compared to industry benchmarks or specific projects.

Related Party Transactions

• The conversion of an unsecured promissory note held by the reporting person (Sandip Patel, a director) into warrants constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential future dilution if the warrants are exercised, but also a sign of insider confidence and improved balance sheet health through debt restructuring. Shareholder approval is required for warrant exercisability.
• Creditors: The conversion of a promissory note into warrants reduces the company's outstanding debt, potentially improving its credit profile.

Next Steps

• Shareholder approval for the exercisability of the acquired warrants and pre-funded warrants.

Key Dates

Recommendation

The director's acquisition of warrants and conversion of debt into equity-like instruments demonstrates insider confidence and a strategic move to manage the company's capital structure. While this reduces immediate debt burden and signals a commitment, the future dilution potential from warrant exercise and the contingency on shareholder approval warrant a 'hold' position. Investors should monitor the shareholder vote and the company's subsequent financial performance.

Keywords

Akari Therapeutics, AKTX, Form 4, Insider Trading, Warrants, Pre-Funded Warrants, Private Placement, Debt Conversion, Director Holdings, SEC Filing, Biotechnology, Pharmaceuticals